As on (17 Apr 2024 | 21:56)
Back To Homepage As on (17 Apr 2024 | 21:56)
Sun Pharma and Bayer sign distribution agreement for second brand of Finerenone in India Back
(17 Jan 2024)

Sun Pharmaceutical Industries and Bayer today announced that both companies have signed an agreement to market and distribute a second brand of Finerenone in India.

Finerenone, a patented medicine is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus.

Under the terms of the agreement, Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa®. Finerenone was first launched by Bayer under the brand name Kerendia TM in 2022.

Top